Yahoo Web Search

Search results

1. www.oranomed.comOrano Med | Home

   www.oranomed.com

   • Cached

   Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells. Discover our mission. Our last news.

   • About us

     Our mission | Orano Med. Orano Med seeks to develop a new...

   • Targeted Alpha Therapy

     Orano Med has equipped itself with all the tools necessary...

   • Pipeline

     A Diverse pipeline of 212 Pb-labeled compounds. Based on the...

   • Industrial platform

     The patented, entirely chemical process, developed by Orano...

   • News

     By clicking “I accept Cookies”, you agree with the cookies...

   • Contact

     Orano Med Contact. By clicking “I accept Cookies”, you agree...

   • Careers

     Orano Med: Orano Med has developed new processes for...

   • Event

     The 12th International Symposium on Targeted Alpha Therapy....

2. People also ask

   What is Orano Med?

   • Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells.

   Orano Med | Home

   www.oranomed.com/en

   See all results for this question

   Where is Orano Med manufactured?

   • Orano Med has 212 Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently investing to further expand its GMP-manufacturing capacities for 212 Pb radiolabeled pharmaceuticals in North America and Europe. More information about Orano Med, visit: www.oranomed.com .

   RadioMedix and Orano Med receive FDA Breakthrough Therapy Design…

   www.businesswire.com/news/home/20240212199538/en/RadioMedix-and-Orano-Med-receive-FDA-Breakthrough-Therapy-Designation-for-AlphaMedixTM-in-gastroenteropancreatic-neuroendocrine-tumors

   See all results for this question

   Why did Orano Med receive FDA approval?

   • This recognition from the FDA reinforces Orano Med’s commitment to make innovative lead-212-based therapies available to the medical community and patients worldwide,” said Julien Dodet, President and Chief Executive Officer of Orano Med.

   RadioMedix and Orano Med receive FDA Breakthrough Therapy Design…

   www.oranomed.com/en/resources/news/2024/radiomedix-and-orano-med-receive-fda-breakthrough-therapy-designation-for-alphamedixtm-in-gastroenteropancreatic-neuroendocrine-tumors

   See all results for this question

   What is Orano Med doing with 212 PB?

   • The company is developing several treatments using 212 Pb combined with various targeting agents. Orano Med has 212 Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently investing to further expand its GMP-manufacturing capacities for 212 Pb radiolabeled pharmaceuticals in North America and Europe.

   RadioMedix and Orano Med receive FDA Breakthrough Therapy Design…

   www.businesswire.com/news/home/20240212199538/en/RadioMedix-and-Orano-Med-receive-FDA-Breakthrough-Therapy-Designation-for-AlphaMedixTM-in-gastroenteropancreatic-neuroendocrine-tumors

   See all results for this question

3. www.businesswire.com › news › homeRadioMedix and Orano Med receive FDA Breakthrough Therapy ...

   www.businesswire.com › news › home

   • Cached

   Feb 12, 2024 · Orano Med is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer using the unique properties of lead-212 ( 212 Pb), a rare alpha-emitting...

4. www.oranomed.com › en › resourcesRadioMedix and Orano Med receive FDA Breakthrough Therapy ...

   www.oranomed.com › en › resources

   • Cached

   Feb 12, 2024 · Orano Med is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212 Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT).

5. oranomed.com › en › about-usOur mission | Orano Med

   oranomed.com › en › about-us

   • Cached

   Our mission | Orano Med. Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells.

   • 
   • 
   • 
   • 

6. www.businesswire.com › news › homeRadioMedix and Orano Med Complete Patient Enrolment in Phase ...

   www.businesswire.com › news › home

   • Cached

   May 16, 2023 · HOUSTON & PARIS-- ( BUSINESS WIRE )--RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase II trial of...

7. www.radiomedix.com › blogs › newsRadiomedix and Orano Med Announce the Initiation of the Phase ...

   www.radiomedix.com › blogs › news

   • Cached

   Jan 3, 2022 · Orano Med is a clinical-stage biotechnology company with the ambition to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 ( 212 Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emmiter Therapy (TAT).

8. www.businesswire.com › news › homeOrano Med Starts Phase I Trial With Alpha Radioligand Therapy

   www.businesswire.com › news › home

   • Cached

   Jan 4, 2023 · PARIS-- ( BUSINESS WIRE )--Orano Med, a clinical stage radiopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial of the alpha radioligand therapy...

9. Images

   • 
   • 
   • 

   View all